Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure (Q38196340)

30 August 2017

1 reference

title

Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure (English)

1 reference

30 August 2017

1 reference

Manoj Kumar Mahapatra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Priyanka Malla

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Rajnish Kumar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Manoj Kumar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

14 March 2014

1 reference

Medicinal Research Reviews

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

1146-1167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24633706%20AND%20SRC:MED&resulttype=core&format=json

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

10 June 2020

cites work

1 reference

Global burden of disease--where does diabetes mellitus fit in?

21 January 2018

1 reference

Diabetes mellitus: new drugs for a new epidemic

21 January 2018

1 reference

SGLT inhibitors in management of diabetes

21 January 2018

1 reference

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

21 January 2018

1 reference

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

21 January 2018

1 reference

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

Structural insights into genetic variants of Na(+)/glucose cotransporter SGLT1 causing glucose-galactose malabsorption: vSGLT as a model structure

21 January 2018

1 reference

A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria

21 January 2018

1 reference

SGLT2 inhibitors: molecular design and potential differences in effect

21 January 2018

1 reference

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

21 January 2018

1 reference

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial

21 January 2018

1 reference

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

21 January 2018

1 reference

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

21 January 2018

1 reference

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data

21 January 2018

1 reference

Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor

21 January 2018

1 reference

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

21 January 2018

1 reference

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

21 January 2018

1 reference

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

21 January 2018

1 reference

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

21 January 2018

1 reference

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

SGLT2 mediates glucose reabsorption in the early proximal tubule.

21 January 2018

1 reference